Oramed is a clinical-stage pharmaceutical company that has evolved into a diversified holding company. Its core technology is an oral drug delivery platform designed to deliver therapeutic proteins, like insulin, through a capsule rather than injection. The flagship drug, ORMD-0801, is an oral insulin capsule for type 2 diabetes that aims to mimic the body's natural insulin pathway via the portal vein. The Phase 3 trial for ORMD-0801 failed in early 2023, though a post-hoc analysis identified subpopulations that responded well, and Oramed plans a targeted 60-patient follow-on trial in the second half of 2026. In March 2026, Oramed transferred its oral delivery platform and insulin program into a joint venture, OraTech, which was then acquired by Lifeward, a medical robotics company. Oramed received a large equity stake in Lifeward and retains responsibility for managing the clinical trial. Beyond its pharma roots, Oramed actively deploys capital across healthcare investments, real estate, and venture capital. Key positions include roughly 17% of Alpha Tau Medical, an oncology company; a significant debt and royalty position in Scilex, a specialty pharma company; and roughly 5% of Nano Dimension, a 3D printing firm. Oramed also authorized up to $30M in real estate investments and co-founded Corner Ally Ventures, an Israeli tech-focused venture fund. Oramed has no product revenue and funds operations from cash reserves, earning income through interest on secured loans, licensing milestones, and equity appreciation.